Empiri, Inc.
Houston, TX
- UEI
- JFK5MSSBKH33
- CAGE
- 8FRB7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 7505 Fannin St Suite 200, Houston, TX 77054, USA
- Website
- empiricancer.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: a cancer diagnostic instrument to measure empirical treatment response -the broader impact/commercial… | National Science Foundation | $1,249,794 | |
| Sbir phase i: a cancer diagnostic instrument to measure empirical treatment response -the broader impact/commercial… | National Science Foundation | $274,930 |
About Empiri, Inc.
Empiri, Inc., a woman-owned, minority-owned small business based in Houston, Texas, develops automated diagnostic instruments for personalized cancer care as a recipient of federal research grants from the National Science Foundation and as a sub-recipient under the National Institutes of Health National Cancer Institute, with no federal contract prime or subcontract work in the current award record.
Empiri is a for-profit corporate entity with WOSB and Asian-Pacific American ownership designations. The vendor's federal footprint is exclusively grant-funded, centered on the Small Business Innovation Research (SBIR) program under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The company's core technology is the E-Slice Assay, a 3D culture-based diagnostic platform that predicts individual cancer patients' responses to anti-cancer drugs within eight days of biopsy or surgery, enabling personalized treatment selection. Empiri has received two NSF SBIR awards as prime recipient: a Phase I Project Grant valued at $1,249,794 awarded August 1, 2023 (ultimate completion August 31, 2025) and a Phase II Cooperative Agreement valued at $1,249,794 awarded July 1, 2026 (ultimate completion June 30, 2028). The Phase II award funds development of an automated tissue slicer and handler (ATSH) instrument to scale the E-Slice assay from research prototype to production-ready, high-capacity clinical operation, including refinement of ATSH design and functionality, scaling of sample preparation workflows, and implementation of customized liquid handling applications. Work is performed in Houston, Texas.
Empiri's customer concentration is currently narrow: two federal agencies across three awards, with NSF accounting for two direct grants and the National Institutes of Health National Cancer Institute funding one sub-award. The sub-recipient relationship runs through the Methodist Hospital Research Institute on a validation study for triple-negative breast cancer (TNBC) treatment selection, awarded January 5, 2026. One award (the Phase I grant) reaches ultimate completion inside the next twenty-four months, creating a recompete opportunity or continuation decision point in that window.
SBA capabilities narrative
single cell sequencing service provider
Quick answers
What is Empiri, Inc.'s UEI?
Empiri, Inc.'s Unique Entity ID (UEI) in SAM.gov is JFK5MSSBKH33.
What is Empiri, Inc.'s CAGE code?
Empiri, Inc.'s CAGE code is 8FRB7.
What is Empiri, Inc.'s primary NAICS code?
Empiri, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Empiri, Inc. located?
Empiri, Inc.'s physical address in SAM.gov is 7505 Fannin St Suite 200, Houston, TX 77054, USA.
Is Empiri, Inc. registered in SAM.gov?
Yes. Empiri, Inc.'s SAM.gov registration is active through July 29, 2027.
What is Empiri, Inc.'s most recent federal award?
Empiri, Inc.'s most recent federal grant award is Sbir phase II: a cancer diagnostic instrument to measure empirical treatment response -the broader impact/commercial… (2538079), from National Science Foundation, on July 1, 2026.
On GovTribe
See Empiri, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors